Skip to main content

Advertisement

SpringerLink
Log in

Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy

  • Meeting Report
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

ACT:

Adoptive cell therapy

APM:

Antigen-presenting machinery

BAs:

Bile acids

B-ALL:

B acute lymphoid leukemia

BC:

Breast cancer

BM:

Bone marrow

CAR:

Chimeric antigen receptors

CIK:

Cytokine-induced killer

CRC:

Colorectal cancer

CRS:

Cytokine-release syndrome

CNS:

Central nervous system

CSPG4:

Chondroitin sulfate proteoglycan 4

CSC:

Cancer stem cells

DC:

Dendritic cells

EOC:

Epithelial ovarian cancer

EV:

Extracellular vesicles

FLIP:

FLICE (FADD-like IL-1β-converting enzyme) inhibitory protein

FXR:

Farnesoid X receptor

GBM:

Glioblastoma multiforme

GITR:

Glucocorticoid-induced tumor necrosis factor receptor

GvHD:

Graft versus host disease

HCC:

Hepatocellular carcinoma

HMGB1:

High-mobility group box 1

ICI:

Immune checkpoint inhibitors

MDSC:

Myeloid-derived suppressor cells

MCA:

Methylcholanthrene

MM:

Multiple myeloma

mTOR:

Mammalian target of rapamycin

NAMPT:

Nicotinamide phosphoribosyltransferase

NSCLC:

Non-small cell lung cancer

ORR:

Objective response rate

OS:

Overall survival

pCR:

Pathologic complete response

PDAC:

Pancreatic ductal adenocarcinoma

PFS:

Progression-free survival

PMN-MDSC:

Polymorphonuclear myeloid-derived suppressor cells

RCC:

Renal cell carcinoma

ROS:

Reactive oxygen species

TAAs:

Tumor-associated antigens

TAM:

Tumor-associated macrophages

TCF-1:

Transgenic T-cell factor 1

TILs:

Tumor-infiltrating lymphocytes

TME:

Tumor microenvironment

Treg:

Regulatory T cells

ZA:

Zoledronic acid

References

  1. Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, Sanchez-Salas R, Ingels A, Oudard S, Moatti A, Buttard B, Bourass S, Germain C, Cathelineau X, Fridman WH, Sautès-Fridman C (2017) Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin Cancer Res 15:4416–4428. https://doi.org/10.1158/1078-0432.CCR-16-2848

    Article  CAS  Google Scholar 

  2. Kather JN, Charoentong P, Suarez-Carmona M, Herpel E, Klupp F, Ulrich A, Schneider M, Zoernig I, Luedde T, Jaeger D, Poleszczuk J, Halama N (2018) High-throughput screening of combinatorial immunotherapies with patient-specific in silico models of metastatic colorectal cancer. Cancer Res 17:5155–5163. https://doi.org/10.1158/0008-5472.CAN-18-1126

    Article  Google Scholar 

  3. Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A (2018) Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer. Nat Commun 1:1092. https://doi.org/10.1038/s41467-018-03301-0.4

    Article  Google Scholar 

  4. Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros MB, Neeb A, Lucianò R, Bravi CA, Nava-Rodrigues D, Dolling D, Prayer-Galetti T, Ferreira A, Briganti A, Esposito A, Barry S, Yuan W, Sharp A, de Bono J, Alimonti A (2018) IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 7714:363–369. https://doi.org/10.1038/s41586-018-0266-0

    Article  CAS  Google Scholar 

  5. Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, Melisi D, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Bicciato S, Blazar BR, Sahin U, Murray PJ, Bronte V (2018) Induction of immunosuppressive functions and NF-κB by FLIP in monocytes. Nat Commun 1:5193. https://doi.org/10.1038/s41467-018-07654-4

    Article  CAS  Google Scholar 

  6. De Simone M, Arrigoni A, Rossetti G, Gruarin P, Ranzani V, Politano C, Bonnal RJP, Provasi E, Sarnicola ML, Panzeri I, Moro M, Crosti M, Mazzara S, Vaira V, Bosari S, Palleschi A, Santambrogio L, Bovo G, Zucchini N, Totis M, Gianotti L, Cesana G, Perego RA, Maroni N, Pisani Ceretti A, Opocher E, De Francesco R, Geginat J, Stunnenberg HG, Abrignani S, Pagani M (2016) Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45(5):1135–1147. https://doi.org/10.1016/j.immuni.2016.10.021

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Keklikoglou I, Cianciaruso C, Güç E, Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonnier A, Ferraro GB, Baer C, Cassará A, Guichard A, Iruela-Arispe ML, Lewis CE, Coussens LM, Bardia A, Jain RK, Pollard JW, De Palma M (2019) Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol 2:190–202. https://doi.org/10.1038/s41556-018-0256-3

    Article  CAS  Google Scholar 

  8. Jachetti E, Cancila V, Rigoni A, Bongiovanni L, Cappetti B, Belmonte B, Enriquez C, Casalini P, Ostano P, Frossi B, Sangaletti S, Chiodoni C, Chiorino G, Pucillo CE, Tripodo C, Colombo MP (2018) Cross-talk between myeloid-derived suppressor cells and mast cells mediates tumor-specific immunosuppression in prostate cancer. Cancer Immunol Res 5:552–565. https://doi.org/10.1158/2326-6066.CIR-17-0385

    Article  CAS  Google Scholar 

  9. Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC (2019) Antibody-Fc/FcR Interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade. Clin Cancer Res 3:989–999. https://doi.org/10.1158/1078-0432.CCR-18-1390

    Article  Google Scholar 

  10. Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ (2018) Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 10:1499–1503. https://doi.org/10.1038/s41591-018-0201-9

    Article  CAS  Google Scholar 

  11. Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G. (2018) Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Sci Transl Med. 10(430): eaao2731. doi: 10.1126/scitranslmed.aao2731.

  12. Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P, Traversari C, Bordignon C, Ciceri F, Ostuni R, Bonini C, Casucci M, Bondanza A (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 6:739–748. https://doi.org/10.1038/s41591-018-0036-4

    Article  CAS  Google Scholar 

  13. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 6371:91–97. https://doi.org/10.1126/science.aan3706

    Article  CAS  Google Scholar 

  14. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 6371:97–103. https://doi.org/10.1126/science.aan4236

    Article  CAS  Google Scholar 

  15. Travelli C, Consonni FM, Sangaletti S, Storto M, Morlacchi S, Grolla AA, Galli U, Tron GC, Portararo P, Rimassa L, Pressiani T, Mazzone M, Trovato R, Ugel S, Bronte V, Tripodo C, Colombo MP, Genazzani AA, Sica A (2019) Nicotinamide phosphoribosyltransferase acts as a metabolic gate for mobilization of myeloid-derived suppressor cells. Cancer Res 8:1938–1951. https://doi.org/10.1158/0008-5472.CAN-18-1544

    Article  Google Scholar 

  16. Sanlorenzo M, Vujic I, Floris A, Novelli M, Gammaitoni L, Giraudo L, Macagno M, Leuci V, Rotolo R, Donini C, Basiricò M, Quaglino P, Fierro MT, Giordano S, Sibilia M, Carnevale-Schianca F, Aglietta M, Sangiolo D (2018) BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD-1 antibody. Clin Cancer Res 14:3377–3385. https://doi.org/10.1158/1078-0432.CCR-17-1914

    Article  CAS  Google Scholar 

  17. Brummelman J, Mazza EMC, Alvisi G, Colombo FS, Grilli A, Mikulak J, Mavilio D, Alloisio M, Ferrari F, Lopci E, Novellis P, Veronesi G, Lugli E (2018) High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. J Exp Med 10:2520–2535. https://doi.org/10.1084/jem.20180684

    Article  CAS  Google Scholar 

  18. Pace L, Goudot C, Zueva E, Gueguen P, Burgdorf N, Waterfall JJ, Quivy JP, Almouzni G, Amigorena S (2018) The epigenetic control of stemness in CD8+ T cell fate commitment. Science 6372:177–186. https://doi.org/10.1126/science.aah6499

    Article  CAS  Google Scholar 

  19. Castella B, Kopecka J, Sciancalepore P, Mandili G, Foglietta M, Mitro N, Caruso D, Novelli F, Riganti C, Massaia M (2017) The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells. Nat Commun 8:15663. https://doi.org/10.1038/ncomms15663

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M (2020) TK Inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway. Cancer Immunol Res. 6:711–722. https://doi.org/10.1158/2326-6066.CIR-17-0594

    Article  CAS  Google Scholar 

  21. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P (2020) CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 373:1803–1813. https://doi.org/10.1056/NEJMoa1510665

    Article  CAS  Google Scholar 

  22. Calabrò L, Morra A, Giannarelli D, Amato G, D’Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, Di Giacomo AM, Maio M (2020) Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 6:451–460. https://doi.org/10.1016/S2213-2600(18)30151-6

    Article  Google Scholar 

Download references

Acknowledgements

This meeting was organized in collaboration with the Board of Directors of NIBIT.

Funding

This meeting was supported in part by unrestricted grant from Roche, Bristol-Meyers Squibb, Novartis, Pierre Fabre, Amgen, MSD Oncology, Biotechne, Incyte, Euroclone and Labospace. It was organized under the auspices of the Italian Association for Cancer Research (AIRC), Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri (OMCeO, Milano), Regione Lombardia, Società Italiana di Cancerologia, Ospedale San Raffaele ed Università Vita-Salute San Raffaele.

Author information

Authors and Affiliations

  1. Unit of Cellular Immunology, IRCCS Ospedale San Raffaele, Milan, Italy

    Matteo Bellone & Arianna Brevi

  2. Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, IRCCS Ospedale San Raffaele, Milan, Italy

    Stefania Bruzzì & Vincenzo Russo

  3. Unit of Experimental Immunology, IRCCS Ospedale San Raffaele, Milan, Italy

    Michela Consonni

  4. Unit of Immunotherapy and Anticancer Innovative Therapeutics, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

    Francesca De Santis & Massimo Di Nicola

  5. Unit of Tumor Immunology, IRCCS Ospedale San Raffaele, Milan, Italy

    Giulia Di Lullo

  6. Unit of Molecular Immunology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy

    Maria Teresa Majorini & Mario Paolo Colombo

  7. Department of Inflammation and Immunology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy

    Anna Pastò

  8. University of Padua, Padua, Italy

    Alberto Amadori

  9. Oncology Unit, ASST Valle Olona, Ospedale di Circolo di Busto Arsizio, Busto Arsizio, Italy

    Marco Bregni

  10. Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy

    Luana Calabrò

  11. European Institute of Oncology IRCCS, Milan, Italy

    Pier Francesco Ferrucci

  12. Department of Haematology, Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Rome, Italy

    Enrico Proietti

Authors
  1. Matteo Bellone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arianna Brevi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefania Bruzzì
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michela Consonni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesca De Santis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giulia Di Lullo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Teresa Majorini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anna Pastò
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Alberto Amadori
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Marco Bregni
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Massimo Di Nicola
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Luana Calabrò
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Pier Francesco Ferrucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Enrico Proietti
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Mario Paolo Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Vincenzo Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to writing the manuscript. MB and VR collected and assembled contributions from all authors. All authors revised and approved the final version of the manuscript.

Corresponding author

Correspondence to Vincenzo Russo.

Ethics declarations

Conflict of interest

No potential conflicts of interest were disclosed by the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bellone, M., Brevi, A., Bruzzì, S. et al. Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy. Cancer Immunol Immunother 69, 1141–1151 (2020). https://doi.org/10.1007/s00262-020-02502-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-020-02502-1

Keywords

Search

Navigation